Effect of lithium carbonate therapy on thyroid immune status in manic depressive patients: a prospective study.
Serum thyroid autoantibodies to thyroglobulin (TG) and thyroid microsomes (M) were measured by ELISA prospectively in 37 manic depressive patients prior to receiving lithium carbonate and during therapy with this drug for a mean of 16.2 months. They were also measured once in 27 normal subjects and several times in five psychiatric patients not receiving lithium. Sixteen patients (43%) had either thyroglobulin, microsomal antibodies or both before receiving lithium therapy. During therapy significant fluctuations in antibody titre, both upwards and downwards were observed in ten out of 12 patients with M antibodies and in nine out of 11 with TG antibodies. The fluctuations in antibody titre are consistent with an immunomodulatory effect of lithium as has been shown in animal studies. It is suggested that psychiatric patients should have thyroid antibodies measured routinely before and during lithium therapy.
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis; D001714:Bipolar Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008094:Lithium / Q000009:adverse effects*; D016651:Lithium Carbonate; D008137:Longitudinal Studies; D008297:Male; D008861:Microsomes / Q000276:immunology; D008875:Middle Aged; D011446:Prospective Studies; D013954:Thyroglobulin / Q000276:immunology; D013961:Thyroid Gland / Q000276:immunology; D013967:Thyroiditis, Autoimmune / Q000209:etiology*
D001323:Autoantibodies; D016651:Lithium Carbonate; D013954:Thyroglobulin; D008094:Lithium